Spotlight on Urology

Credits: 1.00 CME / CNE / CPE
Navigating the Continuum of Care for Advanced Prostate Cancer (mHSPC, CRPC)
Robert Dreicer, MD, MS, MACP, FASCO
Rush University Medical Center

Navigating the Continuum of Care for Advanced Prostate Cancer (mHSPC, CRPC)

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: February 18, 2021
Expires: February 17, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with advanced prostate cancer.

Learning Objectives

After completing this program, participants should be able to:

  1. Explain the different treatment modalities for treating advanced and metastatic prostate cancer including hormonal, cytotoxic, immunologic, targeted, bone-directed, and investigational therapies
  2. Describe and implement the latest advances in the management of advanced prostate cancer across the disease continuum
  3. Personalize treatment decisions for patients with advanced and metastatic prostate cancer based on patient-specific factors, latest best-practice treatment strategies, recent clinical trial data, and expert recommendations

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the managementadvanced prostate cancer. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

With the exception of skin cancer, prostate cancer remains the most common cause of cancer in American men. The majority of patients diagnosed will seek treatment through surgery or radiation, and among those patients, approximately one-third will experience disease recurrence as indicated by elevated prostate specific antigen (PSA). Although androgen deprivation therapy (ADT) achieves temporary tumor control or regression in 90% of these individuals, most patients will ultimately progress to the advanced and/or fatal stage of malignancy, known as castrate-resistant prostate cancer (CRPC), in which the disease spreads to the regional lymph nodes, seminal vesicles, and distant sites such as the bones.

In the past decade, the treatment landscape for advanced prostate cancer has changed dramatically with the introduction of various agents that have demonstrated a survival benefit. Many agents have received FDA approval for the treatment of advanced prostate cancer, including early taxanes, novel endocrine therapies that deprive or block prostate cancers from the effects of androgens, immunotherapeutic strategies that act to induce antitumor responses, new radiopharmaceuticals to target bony metastases, and novel targeted therapies.  These agents are currently in clinical trials to assess their applicability to different phases of the treatment paradigm, either alone or in combination, in an effort to prolong survival while maintaining the patients’ quality of life.  Other novel agents are in late-phase clinical development and are likely to enter the clinic in the near future.

As understanding of the underlying pathology of advanced prostate cancer is further elucidated, the importance of genetic testing (genomic and somatic) to identify biomarkers is playing an increasing role in risk assessment and treatment selection. However, many treatments lack definitive biomarkers and clinicians must rely on their understanding of current best-practice approaches to guide treatment selection for individual patients with advanced prostate cancer. Frequently updated guidelines, along with an increasing number of available agents and the rapid pace of new FDA approvals has challenged many busy clinicians in their ability to stay up to date with current best-practice treatment approaches, which in turn may negatively impact patient outcomes.

This activity aims to address these gaps in clinician knowledge to improve outcomes for patients with advanced and metastatic prostate cancer.

Faculty

Robert Dreicer, MD, MS, MACP, FASCO
Head, Medical Oncology Section
Associate Director for Clinical Research and Deputy Director
University of Virginia Cancer Center
Co-Director Mellon Urologic Institute
Professor of Medicine and Urology
University of Virginia School of Medicine
Charlottesville, Virginia

Conflict of Interest Policy/Disclosure Statement

Dr. Dreicer has served on advisory boards for, Eisai, Janssen, Seattle Genetics, Genentech/Roche, Azuri, Astra Zeneca, Orion, and Novartis

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test.

Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This educational activity is supported by a medical education grant from Advanced Accelerator Applications, Astellas and Pfizer, Inc., Bayer Healthcare Pharmaceuticals, Inc., Exelixis, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., and Sanofi-Genzyme.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: February 18, 2021
Expires: February 17, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with advanced prostate cancer.

Learning Objectives

After completing this program, participants should be able to:

  1. Explain the different treatment modalities for treating advanced and metastatic prostate cancer including hormonal, cytotoxic, immunologic, targeted, bone-directed, and investigational therapies
  2. Describe and implement the latest advances in the management of advanced prostate cancer across the disease continuum
  3. Personalize treatment decisions for patients with advanced and metastatic prostate cancer based on patient-specific factors, latest best-practice treatment strategies, recent clinical trial data, and expert recommendations

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the managementadvanced prostate cancer. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

With the exception of skin cancer, prostate cancer remains the most common cause of cancer in American men. The majority of patients diagnosed will seek treatment through surgery or radiation, and among those patients, approximately one-third will experience disease recurrence as indicated by elevated prostate specific antigen (PSA). Although androgen deprivation therapy (ADT) achieves temporary tumor control or regression in 90% of these individuals, most patients will ultimately progress to the advanced and/or fatal stage of malignancy, known as castrate-resistant prostate cancer (CRPC), in which the disease spreads to the regional lymph nodes, seminal vesicles, and distant sites such as the bones.

In the past decade, the treatment landscape for advanced prostate cancer has changed dramatically with the introduction of various agents that have demonstrated a survival benefit. Many agents have received FDA approval for the treatment of advanced prostate cancer, including early taxanes, novel endocrine therapies that deprive or block prostate cancers from the effects of androgens, immunotherapeutic strategies that act to induce antitumor responses, new radiopharmaceuticals to target bony metastases, and novel targeted therapies.  These agents are currently in clinical trials to assess their applicability to different phases of the treatment paradigm, either alone or in combination, in an effort to prolong survival while maintaining the patients’ quality of life.  Other novel agents are in late-phase clinical development and are likely to enter the clinic in the near future.

As understanding of the underlying pathology of advanced prostate cancer is further elucidated, the importance of genetic testing (genomic and somatic) to identify biomarkers is playing an increasing role in risk assessment and treatment selection. However, many treatments lack definitive biomarkers and clinicians must rely on their understanding of current best-practice approaches to guide treatment selection for individual patients with advanced prostate cancer. Frequently updated guidelines, along with an increasing number of available agents and the rapid pace of new FDA approvals has challenged many busy clinicians in their ability to stay up to date with current best-practice treatment approaches, which in turn may negatively impact patient outcomes.

This activity aims to address these gaps in clinician knowledge to improve outcomes for patients with advanced and metastatic prostate cancer.

Faculty

Robert Dreicer, MD, MS, MACP, FASCO
Head, Medical Oncology Section
Associate Director for Clinical Research and Deputy Director
University of Virginia Cancer Center
Co-Director Mellon Urologic Institute
Professor of Medicine and Urology
University of Virginia School of Medicine
Charlottesville, Virginia

Conflict of Interest Policy/Disclosure Statement

Dr. Dreicer has served on advisory boards for, Eisai, Janssen, Seattle Genetics, Genentech/Roche, Azuri, Astra Zeneca, Orion, and Novartis

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test.

Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This educational activity is supported by a medical education grant from Advanced Accelerator Applications, Astellas and Pfizer, Inc., Bayer Healthcare Pharmaceuticals, Inc., Exelixis, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., and Sanofi-Genzyme.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Urology Presentations

1.00 CME / CNE / CPE
Rush University Medical Center
Navigating the Continuum of Care for Advanced Prostate Cancer (mHSPC, CRPC)

Navigating the Continuum of Care for Advanced Prostate Cancer (mHSPC, CRPC)

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: February 18, 2021
Expires: February 17, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with advanced prostate cancer.

Learning Objectives

After completing this program, participants should be able to:

  1. Explain the different treatment modalities for treating advanced and metastatic prostate cancer including hormonal, cytotoxic, immunologic, targeted, bone-directed, and investigational therapies
  2. Describe and implement the latest advances in the management of advanced prostate cancer across the disease continuum
  3. Personalize treatment decisions for patients with advanced and metastatic prostate cancer based on patient-specific factors, latest best-practice treatment strategies, recent clinical trial data, and expert recommendations

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the managementadvanced prostate cancer. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

With the exception of skin cancer, prostate cancer remains the most common cause of cancer in American men. The majority of patients diagnosed will seek treatment through surgery or radiation, and among those patients, approximately one-third will experience disease recurrence as indicated by elevated prostate specific antigen (PSA). Although androgen deprivation therapy (ADT) achieves temporary tumor control or regression in 90% of these individuals, most patients will ultimately progress to the advanced and/or fatal stage of malignancy, known as castrate-resistant prostate cancer (CRPC), in which the disease spreads to the regional lymph nodes, seminal vesicles, and distant sites such as the bones.

In the past decade, the treatment landscape for advanced prostate cancer has changed dramatically with the introduction of various agents that have demonstrated a survival benefit. Many agents have received FDA approval for the treatment of advanced prostate cancer, including early taxanes, novel endocrine therapies that deprive or block prostate cancers from the effects of androgens, immunotherapeutic strategies that act to induce antitumor responses, new radiopharmaceuticals to target bony metastases, and novel targeted therapies.  These agents are currently in clinical trials to assess their applicability to different phases of the treatment paradigm, either alone or in combination, in an effort to prolong survival while maintaining the patients’ quality of life.  Other novel agents are in late-phase clinical development and are likely to enter the clinic in the near future.

As understanding of the underlying pathology of advanced prostate cancer is further elucidated, the importance of genetic testing (genomic and somatic) to identify biomarkers is playing an increasing role in risk assessment and treatment selection. However, many treatments lack definitive biomarkers and clinicians must rely on their understanding of current best-practice approaches to guide treatment selection for individual patients with advanced prostate cancer. Frequently updated guidelines, along with an increasing number of available agents and the rapid pace of new FDA approvals has challenged many busy clinicians in their ability to stay up to date with current best-practice treatment approaches, which in turn may negatively impact patient outcomes.

This activity aims to address these gaps in clinician knowledge to improve outcomes for patients with advanced and metastatic prostate cancer.

Faculty

Robert Dreicer, MD, MS, MACP, FASCO
Head, Medical Oncology Section
Associate Director for Clinical Research and Deputy Director
University of Virginia Cancer Center
Co-Director Mellon Urologic Institute
Professor of Medicine and Urology
University of Virginia School of Medicine
Charlottesville, Virginia

Conflict of Interest Policy/Disclosure Statement

Dr. Dreicer has served on advisory boards for, Eisai, Janssen, Seattle Genetics, Genentech/Roche, Azuri, Astra Zeneca, Orion, and Novartis

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test.

Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This educational activity is supported by a medical education grant from Advanced Accelerator Applications, Astellas and Pfizer, Inc., Bayer Healthcare Pharmaceuticals, Inc., Exelixis, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., and Sanofi-Genzyme.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: February 18, 2021
Expires: February 17, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with advanced prostate cancer.

Learning Objectives

After completing this program, participants should be able to:

  1. Explain the different treatment modalities for treating advanced and metastatic prostate cancer including hormonal, cytotoxic, immunologic, targeted, bone-directed, and investigational therapies
  2. Describe and implement the latest advances in the management of advanced prostate cancer across the disease continuum
  3. Personalize treatment decisions for patients with advanced and metastatic prostate cancer based on patient-specific factors, latest best-practice treatment strategies, recent clinical trial data, and expert recommendations

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the managementadvanced prostate cancer. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

With the exception of skin cancer, prostate cancer remains the most common cause of cancer in American men. The majority of patients diagnosed will seek treatment through surgery or radiation, and among those patients, approximately one-third will experience disease recurrence as indicated by elevated prostate specific antigen (PSA). Although androgen deprivation therapy (ADT) achieves temporary tumor control or regression in 90% of these individuals, most patients will ultimately progress to the advanced and/or fatal stage of malignancy, known as castrate-resistant prostate cancer (CRPC), in which the disease spreads to the regional lymph nodes, seminal vesicles, and distant sites such as the bones.

In the past decade, the treatment landscape for advanced prostate cancer has changed dramatically with the introduction of various agents that have demonstrated a survival benefit. Many agents have received FDA approval for the treatment of advanced prostate cancer, including early taxanes, novel endocrine therapies that deprive or block prostate cancers from the effects of androgens, immunotherapeutic strategies that act to induce antitumor responses, new radiopharmaceuticals to target bony metastases, and novel targeted therapies.  These agents are currently in clinical trials to assess their applicability to different phases of the treatment paradigm, either alone or in combination, in an effort to prolong survival while maintaining the patients’ quality of life.  Other novel agents are in late-phase clinical development and are likely to enter the clinic in the near future.

As understanding of the underlying pathology of advanced prostate cancer is further elucidated, the importance of genetic testing (genomic and somatic) to identify biomarkers is playing an increasing role in risk assessment and treatment selection. However, many treatments lack definitive biomarkers and clinicians must rely on their understanding of current best-practice approaches to guide treatment selection for individual patients with advanced prostate cancer. Frequently updated guidelines, along with an increasing number of available agents and the rapid pace of new FDA approvals has challenged many busy clinicians in their ability to stay up to date with current best-practice treatment approaches, which in turn may negatively impact patient outcomes.

This activity aims to address these gaps in clinician knowledge to improve outcomes for patients with advanced and metastatic prostate cancer.

Faculty

Robert Dreicer, MD, MS, MACP, FASCO
Head, Medical Oncology Section
Associate Director for Clinical Research and Deputy Director
University of Virginia Cancer Center
Co-Director Mellon Urologic Institute
Professor of Medicine and Urology
University of Virginia School of Medicine
Charlottesville, Virginia

Conflict of Interest Policy/Disclosure Statement

Dr. Dreicer has served on advisory boards for, Eisai, Janssen, Seattle Genetics, Genentech/Roche, Azuri, Astra Zeneca, Orion, and Novartis

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test.

Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This educational activity is supported by a medical education grant from Advanced Accelerator Applications, Astellas and Pfizer, Inc., Bayer Healthcare Pharmaceuticals, Inc., Exelixis, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., and Sanofi-Genzyme.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com